麦济生物冲击港股IPO:核心在研产品赛道拥挤,曾被判专利侵权三生国健

蓝鲸财经
16 Jul

图片来源:视觉中国蓝鲸新闻7月16日讯(记者 屠俊)据港交所7月14日披露,湖南麦济生物技术股份有限公司-B(以下简称“麦济生物”)向港交所提交上市申请书,冲击港股IPO,中金公司为独家保荐人。其《招股书》显示,自2016年成立以来,麦济生物已自主研发并建立一条由八款创新候选产品组成的管线,其中,最核心且进展最快的产品为MG-K10,已经进入临床三期,该产品为一款长效抗IL-4Rα抗体。后续管线还...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10